Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717796 | 0.79 | IDO1 (0.79) | IDO1GAAPOLBMAPTKDM4E | |
| SCHEMBL4715055 | 0.77 | IDO1 (1.00) | IDO1GAAPOLBMAPT | |
| SCHEMBL4715053 | 0.75 | IDO1 (0.54) | IDO1ALOX12GAAPOLBMAPT | |
| SCHEMBL9607546 | 0.75 | ALOX12 (0.56) | IDO1ALOX12CYP1A2TDP1MAPK1 | |
| SCHEMBL1252727 | 0.74 | IDO1 (0.63) | IDO1ALOX12TDP1GAAPOLB | |
| SCHEMBL8081004 | 0.74 | ALOX12 (0.63) | ALOX12CYP1A2TDP1MAPK1MAPT | |
| SCHEMBL1251980 | 0.73 | IDO1 (0.58) | IDO1TDP1GAAPOLBMAPT | |
| SCHEMBL4716917 | 0.73 | IDO1 (0.69) | IDO1GAAPOLBMAPTKDM4E | |
| SCHEMBL4717242 | 0.73 | IDO1 (0.65) | IDO1ALOX12TDP1GAAPOLB | |
| SCHEMBL4716238 | 0.73 | MAPK1 (0.49) | ALOX12CYP1A2TDP1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218383-B1 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-11-05 | — | — | EP | claimed |
| US-20040023927-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| US-6657064-B2 | For use as analgesics | GRUENENTHAL GMBH (DE) | 2003-12-02 | — | — | US | claimed |
| JP-2003511456-A | — | — | 2003-03-25 | — | — | JP | claimed |
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2002-12-05 | — | — | US | claimed |
| EP-1218383-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001027118-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | claimed |
| EP-1218383-B1 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-11-05 | — | — | EP | disclosed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6936631-B2 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040023927-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| US-6657064-B2 | For use as analgesics | GRUENENTHAL GMBH (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
| EP-1218383-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001027118-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | ACHE, P2RX5, CNR1 | IDO1 631/4885ALOX12 3027/4885CYP1A2 236/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | IDO1 2119/4885ALOX12 3782/4885CYP1A2 3197/4885 |
| US-20040023927-A1 | Bicyclic imidazo-5-yl-amine derivatives | ACHE, P2RX5, CNR1 | IDO1 631/4885ALOX12 3027/4885CYP1A2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.